MedPath

Risk of Central Venous Stenosis in Patients With Chronic Renal Failure After IJ Line Placement

Completed
Conditions
Thrombosis
Registration Number
NCT01988766
Lead Sponsor
University of Chicago
Brief Summary

The purpose of this study is to compare the difference in thrombosis as a result of internal jugular (IJ) catheters versus peripherally inserted central catheter (PICC) lines. It is hypothesized that there will be a decreased rate of thrombosis in patients as a result of IJ catheters verses PICC lines.

Detailed Description

In a cohort of patients from Sept 1, 2010 until December 31, 2011 with chronic kidney disease (CKD) has shown that the incidence of IJ thrombosis after short term catheter access occurred in only 1/26 subjects or 4%. The current study is being done to compare this experience with the incidence of thrombosis from PICC lines. A secondary aim will be to determine if variables such as level of renal function, prior history of thrombosis or atherosclerosis contribute to the risk of thrombosis when PICC lines are placed. This data will provide the first comparison of the incidence of thrombotic complications from short term IJ catheter access versus PICC lines.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
1424
Inclusion Criteria
  • subjects who had a PICC line placed at the University of Chicago between September 1, 2010 and December 31, 2011
Read More
Exclusion Criteria
  • subjects under the age of 18
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Incidence of Thrombosis15 months

To calculate the incidence of deep venous thrombosis from PICC lines in patients

Secondary Outcome Measures
NameTimeMethod
Demographic Risk Factor Association with Risk of Thrombosis from PICC or IJ access15 months

To evaluate if factors, known to be associated with thrombosis and atherosclerosis, are associated with the risk of thrombosis from PICC or IJ access. These factors include: renal failure, diabetes, hypertension, cancer, transplant, gender, age or the indication for the access, including antibiotics or chemotherapy.

Trial Locations

Locations (1)

The University of Chicago

🇺🇸

Chicago, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath